Curtiss Puckett
Texas Diabetes Institute(US)Group for the Analysis of Development(PE)
Publications by Year
Research Areas
Diabetes Treatment and Management, Diabetes Management and Research, Metabolism, Diabetes, and Cancer, Pancreatic function and diabetes, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add‐on therapy in subjects with new‐onset diabetes. Results from the E fficacy and D urability of I nitial C ombination T herapy for T ype 2 D iabetes ( EDICT ): a randomized trial(2014)196 cited
- → Durability of Triple Combination Therapy Versus Stepwise Addition Therapy in Patients With New-Onset T2DM: 3-Year Follow-up of EDICT(2020)54 cited
- → Combination therapy with pioglitazone/exenatide/metformin reduces the prevalence of hepatic fibrosis and steatosis: The efficacy and durability of initial combination therapy for type 2 diabetes ( EDICT )(2022)41 cited
- → Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes(2025)15 cited
- → Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment(2025)10 cited
- → 1.8 Initial Triple Combination Therapy is Superior to Stepwise Add-On Conventional Therapy in Newly Diagnosed T2DM (72-OR)(2013)9 cited
- → Type 2 diabetes subgroups and response to glucose‐lowering therapy: Results from the EDICT and Qatar studies(2022)8 cited
- → Insulin Secretion Predicts the Response to Antidiabetic Therapy in Patients With New-onset Diabetes(2021)7 cited
- → Durable HbA1c Reduction with Initial Combination Therapy with Metformin/Pioglitazone/Exenatide in Subjects with New-Onset Diabetes—Six-Year Follow-Up of the EDICT Study(2018)6 cited
- → Insulin secretion is a strong predictor for need of insulin therapy in patients with new‐onset diabetes and HbA1c of more than 10%: A post hoc analysis of the EDICT study(2021)4 cited